Embed Size (px)
Citation preview
Co
1
Corporate Overview
The Trianni Mouse:Best-In-Class Technology for Human Antibody Discovery
David Meininger, PhD, MBAChief Business Officer, Trianni
2
Trianni is a biotech company with the primary scientific mission of creating an optimized and highly versatile platform for isolating fully human monoclonal antibodies.
Our Mission
3
The Trianni MouseTM Difference
4
Distinctive Features of Trianni’s Technology Elimination of endogenous V, D and J gene segments Humanization of all three antibody loci
– H, K, L Designed immunoglobulin alleles
– Targeted insertion of arrays of synthetic antibody gene segments– Optimizations throughout the arrays– Chimeric gene segments (important re FTO)
• Mouse noncoding (regulatory) DNA• Human coding DNA
Platform flexibility– Refinements can be generated quickly– Alternative repertoire mice in development
Core Alleles
5
Heavy (H)μ δ γ3 γ1 γ2b γ2c ε α
44 x VH DH JH Eμ
Kappa (K)39 x VK JK CK
Lambda (L)38 x VL J1CL J2CL J6CL J7CL J6CL J3CL
• Deletion of endogenous V, D and J gene segments
• Chimeric gene segments (human open reading frames paired withmouse regulatory regions)
• Chimeric antibodies (human Vs with mouse Cs)
• Other versions of the core alleles available or under development
In-House Platform Validation
– Antibody repertoire analysis•All gene segments are used; CDR3 lengths and amino acid compositions as in humans
– Immunizations •Ten model antigens tested (human extracellular protein domains)
•mAbs similar to wild type mice in terms of affinity, specificity and epitope coverage
6
Control HHKK HHKKλλ
Trianni Mice: Replete With B Cells and Antibodies
7
Flow Cytometry of Spleen Cells from TRN H/k/l
8
Total lymphocytes MZ B(CD21Hi CD23Lo)
Fo B (CD21+ CD23+)
Gated on:
Total B cells(CD19+ B220+)
In gray, non-B cells in the same staining tube to illustrate the light chain staining backgrounds
B22
0
CD19
CD21
CD
23
Igλ
Igκ
Igλ
Igκ
A Highly Diverse Heavy Chain Repertoire
9
44/44 VHs used
H CDR3 Length Distribution
10
IgM-Sorted Naïve B cells
Heavy Chain CDR3 Compositions
11
Human
Trianni
CDR3s of 15aa in length
non-immune repertoire
12
Five Recent External Evaluation Reports
Three major pharmaceutical companies– Multiple antigens – Comparison to BALB/c and C57BL/6 mice
A (clinical stage) biotechnology/pharmaceutical company– 1 antigen
A start-up small biotechnology company– 1 antigen
Evaluation, Large Pharma #1
13
Target 2, two campaigns (v1 and v2): both WT and Trianni Mice mount strong and similar immune responses
14
Anti-Target 2 Trianni Mouse mAbs Demonstrate Superior Maximum and Average Potency than Wild-Type C57BL/6 Benchmark mAbs
15
Evaluation, Large Pharma #2
- Two human cell surface proteins (Ag1 and Ag2)- A soluble human protein (Ag3)- Immunization:
- Twice a week using Ribi adjuvant- A total of eight injections- Comparison to BALB/c mice
- Three Phase Evaluation:- Immunization data- Immune response quality and diversity; fusion screening data- Detailed characterization of 20 mAbs per target
16
Comparable Titers for All Three Antigens
Trianni
BALB/c
17
MAb Isolation
Hybridoma generation– Electrofusion of lymph node cells
Primary screen– Binding to human antigen
Secondary screen– Cross-reactivity to cynomolgus antigen– Ligand-blocking activity– Off-rates for all binders (using supernatants)– Epitope competition (using supernatants)
18
Primary Screening Results
Fusion parameters and primary binding similar to BALB/c
19
Secondary Screening Results
Extended characterization of hu-Ag+ supernatants similar to BALB/c
Ligand blockingCyno cross-reactivityOff-rates (majority of clones in 10-2 to 10-3 range using supernatants)Epitope coverage (Ag3 – 6/7 Trianni, 5/7 BALB/c)
20
Tertiary Analysis
Subclone ≤ 20 hybridomas from each Tg animal/Ag– Determine productivity of
hybridomas– Characterize EC50, IC50 and KD for
purified mAbs– Assess diversity of selected mAbs
21
• Good quality antibodies were produced relative to control mice and benchmark antibodies
• Reasonable diversity seen with sequenced antibodies
Data Summary
22
Pharma #2 performed a side-by-side comparison
with another in-vivo platform “The Trianni Mouse
performed much better…the results were not
even close.” (Quote From Pharma #2)
TRIANNI Strongly Preferred in Side-by-Side Comparison
Evaluation, Large Pharma #3
- Independent evaluation at two sites (US and Europe)- Multiple human antigens in both cases- Immunization:
- RIMMS vs. conventional
- Hybridomas and single B cell cloning- Antibody reformatting
23
Trianni Mouse-Derived Hybridoma Deliver Normal Production Yields and mAb Quality
24
Purified Trianni MAbs Exhibit Sub-nM to nM Binding Affinities
25
Affinity in subnM-nM range for both Trianni and BALB/c
Apparent Affinity on Soluble Protein
Kd app (M)
Mean ± SD (M)4.8 x 10-10 ± 5.4 x 10-10
Mean ± SD (M)3.9 x 10-09 ± 9.2 x 10-09
Trianni mAbs Can Be Successfully Reformatted into Fully-Human IgG
26
● Sequence retrieved by RT-PCR from hybridoma
● Cloning VH and VL sequence into mammalian expression vectors
● Similar production yield and mAb quality from reformatted mAbs and Balb/c
Anti CD38 Clones
PurifiedBatch
Productivity mg/L
PuritySDS-PAGE
Mass spectrometryMW (Da)
ELISA on CD38 EC50 (nM)
LC HC Reformatted Hybridoma
109HHKK-3 VA115073 135 98 % 23 301 51 486 0.23 0.46
820HHKK-3 VA115081 108 > 99 % 23 223 50 445 0.37 1.26
1195HHKK-3 VA115072 152 99 % 23 356 50 939 0.42 0.21
1370HHKK-3 VA115079 77 > 99 % 23 257 50 417 0.30 1.40
1883HHKK-3 VA115080 73 94 % 23 235 51 745 0.10 0.06
4487HHKK-5 VA115098 26 99 % 23 359 50 050 0.07 0.26
4527HHKK-5 VA115099 42 99 % 24 011 51 043 0.10 0.15
992HHKK-7 VA115100 62 99 % 23 390 50 443 0.10 0.05
from reformatted Balb/c 30- 200
27
Business Model
Our Partners
28
Below is representative of our publically announced partnerships
DISCOVERY PARTNERS
CRO PARTNERS
STANFORDJANSSE
NUAB
TRIANNI Benefits
29
Small company means: - easy access to our experts - lean processes (quicker time to use of our platform) - personal relationships
60 years combined industry experience
Representation in key biotech locations - San Francisco, CA (West Coast, USA)- Research Triangle Park, NC (East Coast, USA)- Austria (Europe)
Flexibility to create a custom partnership to match your needs Forward-thinking leadership Faster turn-around time Technical support, if needed An investment in your company. We value our partners and
want you to succeed!
